Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep324 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Long-term efficacy and safety of flash glucose monitoring system: 30-month real-life experience

Rodia Cosimo , Falcetta Pierpaolo , Bertolotto Alessandra , Bianchi Cristina , Del Prato Stefano , Aragona Michele

The use of FreeStyle Libre (FSL) or Flash Glucose Monitoring (FGM) system becomes increasingly popular among people with diabetes, especially type 1 diabetes (T1DM) and several randomized and controlled study have shown how its use is associated with less and shorter hypoglycemic events without deterioration of HbA1c. Nevertheless, there are not yet consistent and lasting data reporting the impact of FGM in people with diabetes in real-life conditions. In this study we evaluat...

ea0070aep332 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Immune checkpoint inhibitors (ICIs) and ‘Fulminant Diabetes’: Two emblematic cases

Sgro’ Daniele , Giannarelli Rosa , Aragona Michele , Viola Nicola , Cosentino Giada , Brancatella Alessandro , Latrofa Francesco , Del Prato Stefano , Santini Ferruccio , Marcocci Claudio , Lupi Isabella

Context: Programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) are key regulators in T-cell activation and tolerance. Nivolumab (PD-1 inhibitor) and Atezolizumab (PD-L1 inhibitor) are monoclonal antibodies approved for the treatment of several types of advanced cancers. Immune checkpoint inhibition caused by these drugs can result in immune-related adverse events (irAEs) New-onset diabetes mellitus has been reported in fewer than 1% of patients an...